Literature DB >> 31230854

Management of an aggressive giant cell granuloma of the mandible with denosumab: a case report.

M Hameed1, J E O'Connell2, S N Rogers3.   

Abstract

The management of giant cell granulomas is challenging, and aggressive lesions have a high tendency to recur after enucleation alone. Based on assumptions regarding cell type and receptors, multiple pharmacological adjuncts have been used to manage them. We describe the use of denosumab, which was successfully used as a single method of treatment, suggesting that it may be a viable alternative or adjunct to operation on giant cell granulomas of the jaws. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Denosumab; Giant Cell Granuloma; Medication related osteonecrosis; Monoclonal Antibodies; Osteoclasts; RANKL; neo-ossification

Year:  2019        PMID: 31230854     DOI: 10.1016/j.bjoms.2019.05.023

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  1 in total

1.  Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.

Authors:  Yoon Ji Jina Rhou; Che-Jen Wang; Minh Nguyen; Joel A Vanderniet; Craig F Munns; Hedley Coleman; James Kim; Deborah Jane Holmes-Walker; Lydia Lim; Christian M Girgis
Journal:  Calcif Tissue Int       Date:  2022-01-28       Impact factor: 4.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.